Practical approach to management of chronic lymphocytic leukemia

por Smolej, Lukáš, Šimkovič, Martin
Publicado 2015

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

por Smolej, Lukáš, Vodárek, Pavel, Écsiová, Dominika, Šimkovič, Martin
Publicado 2021

Sulphoraphane Affinity-Based Chromatography for the Purification of Myrosinase from Lepidium sativum Seeds

por Galádová, Helena, Polozsányi, Zoltán, Breier, Albert, Šimkovič, Martin
Publicado 2022

Is percutaneous computed tomography-guided biopsy sufficient to establish indolent lymphoma transformation?

por Dvorak, Petr, Hoffmann, Petr, Simkovic, Martin, Jandura, Jiri, Nova, Marketa
Publicado 2018

Optimisation of Recombinant Myrosinase Production in Pichia pastoris

por Rosenbergová, Zuzana, Kántorová, Kristína, Šimkovič, Martin, Breier, Albert, Rebroš, Martin
Publicado 2021

Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders

por Pospiskova, Jana, Smolej, Lukas, Belada, David, Simkovic, Martin, Motyckova, Monika, Sykorova, Alice, Stepankova, Pavla, Zak, Pavel
Publicado 2019

A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia

por Vodárek, Pavel, Écsiová, Dominika, Řezáčová, Vladimíra, Souček, Ondřej, Šimkovič, Martin, Vokurková, Doris, Belada, David, Žák, Pavel, Smolej, Lukáš
Publicado 2022

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

por Šimkovič, Martin, Motyčková, Monika, Belada, David, Vodárek, Pavel, Kapoor, Rahul, Jaffar, Hamna, Vrbacký, Filip, Žák, Pavel, Smolej, Lukáš
Publicado 2015

Effects of Sulforaphane-Induced Cell Death upon Repeated Passage of Either P-Glycoprotein-Negative or P-Glycoprotein-Positive L1210 Cell Variants

por Bertova, Anna, Kontar, Szilvia, Polozsanyi, Zoltan, Simkovic, Martin, Rosenbergova, Zuzana, Rebros, Martin, Sulova, Zdena, Breier, Albert, Imrichova, Denisa
Publicado 2022

PB1945: PATIENT PERSPECTIVES ON CLL TREATMENT SIDE EFFECTS: A SUB-ANALYSIS OF THE VOICE SURVEY

por Tam, Constantine, Pinilla-Ibarz, Javier, Karakus, Volkan, Pavlovsky, Miguel, Stilgebauer, Stephan, Šimkovič, Martin, Fenili, Ana Cristina, Miroli, Miguel Augusto, Castillo, Carolina Garcia, Huntley, Kathryn, Moura, Catherine, Piotrowski, Fernando, Mattar, Mervat
Publicado 2023

Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL

por Tam, Constantine, Pinilla-Ibarz, Javier, Castillo, Carolina G., Fenili, Ana Cristina, Huntley, Kathryn, Karakus, Volkan, Mattar, Mervat, Miroli, Miguel A., Moura, Catherine, Pavlovsky, Miguel, Piotrowski, Fernando, Šimkovič, Martin, Stilgenbauer, Stephan
Publicado 2023

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE stu...

por Greil, Richard, Tedeschi, Alessandra, Moreno, Carol, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Gill, Devinder, Gribben, John G., Flinn, Ian W., Wang, Zhengyuan, Cheung, Leo W. K., Nguyen, Aaron N., Zhou, Cathy, Styles, Lori, Demirkan, Fatih
Publicado 2021

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE...

por Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Novak, Jan, Strugov, Vladimir, Gill, Devinder, Gribben, John G., Kwei, Kevin, Dai, Sandra, Hsu, Emily, Dean, James P., Flinn, Ian W.
Publicado 2022

Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks

por Mikulkova, Zuzana, Manukyan, Gayane, Turcsanyi, Peter, Kudelka, Milos, Urbanova, Renata, Savara, Jakub, Ochodkova, Eliska, Brychtova, Yvona, Molinsky, Jan, Simkovic, Martin, Starostka, David, Novak, Jan, Janca, Ondrej, Dihel, Martin, Ryznerova, Pavlina, Mohammad, Lekaa, Papajik, Tomas, Kriegova, Eva
Publicado 2021

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia

por Salles, Gilles, Bachy, Emmanuel, Smolej, Lukas, Simkovic, Martin, Baseggio, Lucile, Panovska, Anna, Besson, Hervé, Healy, Nollaig, Garside, Jamie, Iraqi, Wafae, Diels, Joris, Pick-Lauer, Corinna, Spacek, Martin, Urbanova, Renata, Lysak, Daniel, Hermans, Ruben, Lundbom, Jessica, Callet-Bauchu, Evelyne, Doubek, Michael
Publicado 2019

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

por Ghia, Paolo, Pluta, Andrzej, Wach, Małgorzata, Lysak, Daniel, Šimkovič, Martin, Kriachok, Iryna, Illés, Árpád, de la Serna, Javier, Dolan, Sean, Campbell, Philip, Musuraca, Gerardo, Jacob, Abraham, Avery, Eric J., Lee, Jae Hoon, Usenko, Ganna, Wang, Min Hui, Yu, Ting, Jurczak, Wojciech
Publicado 2022

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

por Šimkovič, Martin, Turcsányi, Peter, Špaček, Martin, Mihályová, Jana, Ryznerová, Pavlína, Maco, Mária, Vodárek, Pavel, Écsiová, Dominika, Poul, Hynek, Móciková, Heidi, Zuchnická, Jana, Panovská, Anna, Lekaa, Mohammad, Oršulová, Martina, Prchlíková, Adéla, Stejskal, Lukáš, Mašlejová, Stanislava, Brychtová, Yvona, Bezděková, Lucie, Papajík, Tomáš, Lysák, Daniel, Trněný, Marek, Smolej, Lukáš, Doubek, Michael
Publicado 2023

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

por Munir, Talha, Moreno, Carol, Owen, Carolyn, Follows, George, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Osterborg, Anders, Robak, Tadeusz, Simkovic, Martin, Stevens, Don, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Keqin, Qi, Qianya, Parisi, Lori, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Howes, Angela, Caces, Donne Bennett, Niemann, Carsten U., Kater, Arnon P.
Publicado 2023

S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY

por Ondrisova, Laura, Seda, Vaclav, Hoferkova, Eva, Chiodin, Giorgia, Hlavac, Krystof, Kostalova, Lenka, Filip, Daniel, Faria Zeni, Pedro, Panovska, Anna, Plevova, Karla, Pospisilova, Sarka, Simkovic, Martin, Vrbacky, Filip, Lysak, Daniel, Fernandes, Stacey M., Davids, Matthew S., Maiques-Diaz, Alba, Charalampopoulou, Stella, Martin-Subero, Jose I, Brown, Jennifer R, Doubek, Michael, Forconi, Francesco, Mayer, Jiri, Mraz, Marek
Publicado 2023

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

por Tam, Constantine S., Robak, Tadeusz, Ghia, Paolo, Kahl, Brad S., Walker, Patricia, Janowski, Wojciech, Simpson, David, Shadman, Mazyar, Ganly, Peter S., Laurenti, Luca, Opat, Stephen, Tani, Monica, Ciepluch, Hanna, Verner, Emma, Šimkovič, Martin, Österborg, Anders, Trněný, Marek, Tedeschi, Alessandra, Paik, Jason C., Kuwahara, Sowmya B., Feng, Shibao, Ramakrishnan, Vanitha, Cohen, Aileen, Huang, Jane, Hillmen, Peter, Brown, Jennifer R.
Publicado 2020